anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To obtain a pharmaceutical formulation that has improved appearance instability of pharmaceutical formulation by interaction of mixed medicines, especially improved expansion of formulation.  <P>SOLUTION: The pharmaceutical formulation comprises (a) a mixture obtained by mixing ibuprofen with tranexamic acid in the weight ratio of 1:1-2 or (b) a mixture obtained by mixing ibuprofen with tranexamic acid in the weight ratio of 1:0.1-5 and further at least one kind of a main agent selected from d-chlorpheniramine maleate, dihydrocodeine phosphate, dl-methylephedrine hydrochloride and potassium guaiacolsulfonate. In the case of (a), 0.1-5 parts wt. of a desiccating agent based on 1 part wt. of mixed ibuprofen is enclosed and packed. In the case of (B), 0.01-10 parts wt. of a desiccating agent is enclosed and packed into a bottle.  <P>COPYRIGHT: (C)2007,JPO&INPIT
A method of inhibiting the growth of a bacterial species in a human or non-human vertebrate employs the antimicrobial (i.e., antibiotic) properties of 5-aminosalicylates. These antimicrobial properties are also employed in an antimicrobial method of inhibiting the growth of a bacterial species in a foodstuff and in foodstuffs containing a 5-aminosalicylate compound. Pharmaceutical compositions, foodstuffs, food containers, food-handling implements, cleansers, polishes, paints, sprays, soaps, or detergents comprise 5-aminosalicylate compounds, such as mesalamine, sulphasalazine, olsalazine, ipsalazine, salicylazobenzoic acid, balsalazide, or conjugated bile acids, including ursodeoxycholic acid-5-aminosalicylic acid. The present pharmaceutical compositions can be formulated for ingestive, colonic, or topical non-systemic delivery systems or for any systemic delivery systems. Formulation can be for human or veterinary administration. Using the method and pharmaceutical preparations the growth of bacterial species, such as Clostridium perfringens, Clostridium difficile, Clostridium botulinum, and Clostridium tetani can be inhibited.
Participants who are randomly assigned to the wait-list group will receive no intervention during the first 12 weeks. Not only will they serve as the comparative group, they will also serve as their own control and receive the same yoga intervention at the end of 12 weeks when the immediate treatment group completed their program.
OBJECTIVE: The Surgical Apgar Score quantifies three intraoperative parameters: lowest heart rate, lowest mean arterial pressure, and estimated blood loss (EBL). This scoring system predicts postoperative complications based on these measured factors. The aim of this study was to investigate the value of modified Surgical Apgar Score (mSAS) in predicting postoperative complications in patients with rectal cancer treated with robotic surgery in order to improve the survival and quality of life of rectal cancer patients.
METHODS: The study included patients with rectal cancer who underwent robotic surgery in the Department of Gastrointestinal Surgery at the First Affiliated Hospital of Nanchang University from January 2015 to December 2023. In minimally invasive surgery, we developed a modified Surgical Apgar Score (mSAS) tailored for robotic rectal cancer surgery, incorporating an adjusted threshold for EBL. This threshold was derived from quartile analysis of a cohort of 524 patients, with a median EBL of 100 mL (IQR 80-130 mL). We analyzed the association of postoperative complications with low mSAS.
RESULTS: This study included 524 patients, of which 91 (17.4%) experienced complications and 22 (4.2%) suffered severe complications. mSAS of 6 provided maximal Youden index and were determined as the cut-off values. The area under the ROC curve for predicting complications using the mSAS was 0.740. Univariate and multivariate analyses indicated that an older age, lower tumor localization, longer operation time, radiotherapy alone, combined chemoradiotherapy, and lower mSAS as independent risk factors for complications. The AUC of the prediction nomogram was 0.834 (95% CI 0.774-0.867). The calibration curve demonstrated excellent concordance with the nomogram, indicating the prediction curve ft the diagonal well.
CONCLUSION: This study suggests that mSAS might be a valuable predictive indicator for postoperative complications following robotic rectal cancer surgery, with potentially higher clinical utility.
Subjects received MAP0004 on Day 1 of Visit 2, Ketoconazole on Days 3 through 6 of Visit 2, and MAP0004 again on Day 6 of Visit 2. Subjects then returned for Visit 3, 7-11 days from the end of Visit 2. At Visit 3 subjects received 1.0 mg IV DHE (Intravenous Dihydroergotamine Mesylate).
Heart failure is a syndrome that may develop when cardiovascular disease progresses or is insufficiently treated and associated with a poor quality of life, high mortality rates, and increased healthcare expenditures. Prevention and treatment of heart failure are therefore of utmost importance. New therapies in patients with cardiovascular disease have recently been shown to be effective in the prevention and sometimes treatment of heart failure, and additional research is underway. Specifically, in high-risk patients with either (a combination of) diabetes, chronic kidney disease, and/or heart failure, three specific drug classes [sodium-glucose co-transporter 2 inhibitors (SGLT2i), glucagon-like peptide 1 receptor agonists (GLP-1-RAs), and non-steroidal mineralocorticoid receptor antagonists (MRAs)] have taken centre stage in therapeutic approach for these high cardiovascular risk patients. The commonality of these drugs is the finding that they improve cardiovascular and renal endpoints across the cardiorenal continuum and SGTL2i have already proved effective in all subtypes of heart failure, while we await data on non-steroidal MRA therapy in heart failure. The story may be different for GLP-1-RA in patients with established heart failure, but these drugs are effective in reducing cardiovascular events in patients with diabetes. Taken together, these new therapies advance the treatment and improve the associated outcomes of patients with cardiorenal disease and diabetes, with similar characteristics and effectiveness in different conditions.
Standard care program including strengthening, flexibility, aerobic conditioning, modalities and manual mobilization techniques. Supervised 10-week program, 2 times a week.
BACKGROUND/PURPOSE: To describe two cases of patients diagnosed with chronic postoperative cystoid macular edema associated with noninfectious posterior uveitis who had limited treatment response to previous corticosteroid modalities and then received a single intravitreal fluocinolone 0.18-mg implant. Chronic postoperative cystoid macular edema (CME) may occur after intraocular surgery and is a common cause of postoperative visual loss. Sometimes called Irvine-Gass syndrome or persistent pseudophakic CME, chronic postoperative CME complicates roughly 0.1% to 2.0% of low-risk, small-incision phacoemulsification surgeries. There are a number of conventional approaches to chronic postoperative CME management, including topical corticosteroids with or without nonsteroidal anti-inflammatory drugs, intravitreal corticosteroid injections, and vascular endothelial growth factor (VEGF) inhibitor injections, but these options have several limitations. A major shortcoming of conventional formulations of anti-inflammatory therapies for chronic postoperative CME (i.e., topical drops, intraocular, and periocular injections) is the need for repeated dosing in chronic cases, which is expensive and burdensome to patients.
METHODS: Series of two case reports. Patient 1, a 75-year-old Latina woman, presented with a history of longstanding, recurrent inflammation after cataract extraction and subsequent vitreoretinal surgeries. Patient 2, an 85-year-old white woman, presented with acute blurred vision, swelling, and pain 5 years after cataract surgery and laser peripheral iridotomy. Both were diagnosed with chronic postoperative CME and ultimately treated with the 3-year sustained-release fluocinolone acetonide intravitreal implant (FAi) 0.18 mg.
RESULTS: Compared with baseline, both patients experienced resolution of their disease symptoms, >3 lines of visual acuity improvement, and macular edema reduction of 56.2% and 38.4% at 15 and 6 months, respectively, after the fluocinolone implant. No steroid related adverse events including any intraocular pressure measurement >25 mmHg were observed.
CONCLUSION: A single intravitreal fluocinolone 0.18-mg implant can effectively and safely treat vision loss and increased central macular thickness because of chronic postoperative cystoid macular edema associated with noninfectious posterior uveitis. The FAi 0.18 mg provides a safe, long-acting, low-dose anti-inflammatory treatment in patients with noninfectious posterior-segment inflammation associated with chronic postoperative CME.
<P>PROBLEM TO BE SOLVED: To provide a method for helping detect the presence of pancreatic cancer that expresses a 36P6D5 protein of SEQ. ID NO. 2 and a kit for detecting the presence of pancreatic cancer in an individual.  <P>SOLUTION: The step of determining a level of expression of a 36P6D5 protein evidenced in a test biological sample selected from among a group, consisting of pancreatic tissue, serum, blood, and urine from an individual by contacting the sample or a portion thereof with an antibody that specifically binds the protein and the step of comparing the level, thus determined to a level of expression of the 36P6D5 protein evidenced in a corresponding normal biological sample selected from among a group consisting of pancreatic tissues, serum, blood, and urine are included. Elevated expression for the 36P6D5 protein, evidenced in the test sample relative to the normal sample, is an indication of the presence of pancreatic cancer in the individual.  <P>COPYRIGHT: (C)2008,JPO&INPIT
ARM 4: Meals + registered dietitian services + occupational therapy services. Participants in this arm will receive 14 frozen meals, delivered 1x/week, for 3-months as well as the same nutrition education and fall prevention handouts as provided in Arms 1-3. Additionally, participants will receive the combination of dietitian and OT services as provided in Arms 2 and 3 and have the same autonomy to make their own weekly meal selections from a curated list provided by the dietitian.
Male or female patients with histologically proven cutaneous melanoma received the investigational High-Dose (HD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
Rarely, high doses of cyclically pulsed intravenous methylprednisolone (usually for the treatment of exacerbations of multiple sclerosis at doses of 1 gram/day) can induce a toxic form of acute hepatitis. The time to onset of this form of steroid-induced liver injury can be several weeks or longer. Resolution has been observed after discontinuation of treatment. However, serious liver injury can occur, sometimes resulting in acute liver failure and death. Discontinue intravenous methylprednisolone if toxic hepatitis occurs. Since recurrence has occurred after re-challenge, avoid use of high dose intravenous methylprednisolone in patients with a history of toxic hepatitis caused by methylprednisolone.
In accordance with the present invention, there are provided combinational therapeutic methods for the in vivo inactivation or inhibition of formation (either directly or indirectly) of species which induce the expression of nitric oxide synthase, as well as reducing nitric oxide levels produced as a result of .NO synthase expression. In contrast to the inhibitory approach described in the prior art (i.e., wherein the function of the enzymes responsible for nitric oxide production is inhibited), the present invention employs a combination of inactivation (or inhibition) and scavenging approach whereby the stimulus of nitric oxide synthase expression is inactivated, or the production thereof is inhibited, and overproduced nitric oxide is bound in vivo to a suitable nitric oxide scavenger. The resulting complexes render the stimulus of nitric oxide synthase expression inactive (or inhibit the production thereof), and nitric oxide harmless. The resulting complexes are eventually excreted in the urine of the host. In another aspect, the present invention relates to reducing elevated nitric oxide levels associated with infectious and/or inflammatory conditions (and the treatment thereof), employing a combinational therapeutic method wherein an agent for the treatment of the infectious and/or inflammatory condition is coadministered along with a dithiocarbamate compound as a scavenger of overproduced nitric oxide. Further in accordance with the present invention, there are provided compositions and fomulations useful for carrying out the above-described methods.
Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 weeks. Participants are not currently in a depressive episode per the Mini International Neuropsychiatric Interview (MINI) and are not experiencing clinically significant depression symptoms assessed using the Montgomery Asberg Depression Rating Scale (MADRS) with a score \</= 10.
NEW MATERIAL:A compound expressed by formula I (A is amino acid residue of glycine, sarcosine, alanine, N-methylalanine beta-alanine or proline; R1 is alkoxy or alkyl; R2 is H, halogen or linked with R1 to form methylenedioxy) or a salt thereof. EXAMPLE:Bis[4-(N-carboxysulfamoyl)-7-methoxy-2-benzofuranyl]ketone. USE:A remedy for diabetic complications, having inhibitory action on both aldose reductase and blood platelet agglutination, and capable of exhibiting improved effect on prevention and treatment of subjective and autonomic disorder, diabetic renopathy, and eye diseases, e.g. retinopathy or cataract. PREPARATION:A compound expressed by formula II (R3 is alkyl) is hydrolyzed to give the compound expressed by formula I. The compound expressed by formula II is novel, and obtained by chlorosulfating a compound expressed by formula III, and reacting the resultant compound expressed by formula IV with a compound expressed by the formula H-A-OR3.
This is a randomized, double-blind (neither the researchers nor the participants know what treatment the participant is receiving), active-controlled, multicenter study (more than 1 study site) in elderly participants with TRD to assess the efficacy, safety, and tolerability of flexible doses of intranasal esketamine plus a newly initiated oral antidepressant compared with a newly initiated oral antidepressant (active comparator) plus intranasal placebo. The study will consist of 3 phases: Screening/Prospective Observational Phase (4 to 7 weeks), Double-blind induction Phase (4 weeks), Follow up Phase (2 weeks). Participants who rollover into a long-term open-label safety study will not participate in the Follow-up Phase. At the start of the Screening/Prospective observational Phase, participant must have had documented nonresponse to at least one antidepressant treatment (based on Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire \[MGH-ATRQ\] criteria) in the current episode of depression, and the participant is taking a different oral antidepressant treatment on the MGH-ATRQ for at least the previous 2 weeks at or above the minimum therapeutic dose. This antidepressant treatment will be discontinued prior to the double-blind induction Phase. Participants taking benzodiazepines (at dosages equal to or less than the equivalent of 6 mg/day of lorazepam) and/or permitted non-benzodiazepine sleep medications (example, zolpidem, zaleplon) during the screening/prospective observational phase can continue these medications. All participants will start with first dose (Day 1 as 28 milligram \[mg\]); second dose (Day 4) is either 28 or 56 mg. All subsequent doses may be 28, 56 or 84 mg. After the first dose, all dosing decisions are determined by the investigator based on efficacy and tolerability. In addition, each participant will be assigned to receive 1 of 4 oral antidepressant medications from 2 different classes of antidepressant treatments, a Selective Serotonin Reuptake Inhibitor (SSRI) (escitalopram or sertraline) or a Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) \[duloxetine or venlafaxine extended release (XR)\], initiated on Day 1 and continued through the double-blind induction Phase. Participants will be primarily evaluated for improvement in depressive symptoms as assessed by change in Montgomery Asberg Depression Rating Scale (MADRS) total score at Week 4. Participants' safety will be monitored throughout the study.
The invention takes the theory of traditional Chinese medicine as guidance, combines years of clinical experience and combines related Chinese herbal medicines as a prescription. Provides a Chinese herbal medicine foot bath powder for patients with hyperuricemia, which has the effects of tonifying the kidney and dispelling wind, dampness and cold. The foot bath therapy is used for stimulating acupuncture points of human body and nerves, dredging channels and collaterals, smoothing qi and blood, recovering viscera functions, regulating metabolism, tonifying kidney and benefiting qi. So as to achieve the effect of quickly reducing uric acid. The foot bath powder is prepared from the following raw materials in parts by weight: 15g of beautiful sweetgum fruit, 12g of giant knotweed rhizome, 12g of glabrous greenbrier rhizome, 12g of Chinese angelica, 10g of sunflower disc, 12g of astragalus root, 15g of kelp, 12g of suberect spatholobus stem, 12g of periploca forrestii, 10g of motherwort, 10g of glossy privet fruit, 10g of actinolite, 12g of szechuan lovage rhizome, 8g of turmeric, 10g of garden balsam stem, 12g of divaricate saposhnikovia root, 12g of white paeony root, 12g of danshen root, 12g of epimedium herb, 12g of dodder, 10g of Chinese mugwort leaf, 12g of cassia twig, 11. The external foot bath powder has the effects of dispelling wind, dredging collaterals, regulating qi and blood, tonifying liver and kidney and reducing uric acid, and is suitable for hyperuricemia.
The invention discloses an essential hypertension radical treatment fully playing efficacies of traditional Chinese medicines and cooperating with skin scraping, moxibustion and blood pricking. 24 traditional Chinese machines comprise fried rhubarb, leonurus japonicus, rhynohophylla, radix aconiti, radix salviae miltiorrhizae, gastrodia elata, sophora flower, chrysanthemum, prunella vulgaris, radix achyranthis bidentatae, alisma plantago-aquatica, plantain seed, exocarpium citri rubrum, radix aucklandiae, rhizoma cyperi, radix bupleuri, apocynum venetum, semen cassiae, folium ginkgo, herba epimedii, full scorpion, radix polygoni multiflori, leech and muscardine silkworm, and coarse powder passes through a 60-mesh sieve. 24 g of the plant medical powder of the coarse powder is taken and is soaked in a vacuum bottle for 6 hours or more by boiled water with the temperature of 100 DEG C or more, and 600 ml of the juice is taken and is administered with 200 mL every time. While the soaked liquid is administered, 2 g of an animal powder of a step 1.2 as described in the specification is administered after being dissolved with a medical juice and is administered for three times a day. The used plant medicines are in the low-temperature soaking form, so that effective ingredients of the plant medicines and the animal crude medicine are directly administered after being dissolved, animal proteins are kept to be not damaged by high temperature and high pressure, the formula is reasonable, the medicines have specific effects and great power, turbidity toxins of five internal organs are removed, sedimentary blood stasis of six hollow organs is dredged, converted matters are allowed to be timely discharged by urine and stool, so same-kind antihypertensive drugs cannot reach. At the same time, with cooperation of skin scraping, moxibustion and blood pricking, dialectical therapy aiming at various types of hypertension is carried out, and thus the objective of radical treatment of hypertension is achieved.
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for preventing and treating skin chap and a traditional Chinese medicine product thereof, which comprise indocalamus, dragon's blood, rheum officinale, catechu, radix sophorae flavescentis, radix stemonae and safflower. Indocalamus is a monarch drug with the main efficacy of clearing heat and cooling blood and also has the function of astringing and stopping bleeding. The dragon's blood, the rhubarb and the catechu are ministerial drugs, and play a role in cooperation, so as to jointly enhance the blood circulation and the repair function of the skin. Kuh-seng, stemona root and safflower are adjuvant drugs which can enhance the heat clearing, dampness eliminating, blood circulation activating and pain relieving effects of indocalamus in compatibility. The compatibility of the medicinal compositions mainly expands around the aspects of dispersing blood stasis, activating blood circulation, clearing heat, cooling blood, relieving pain, diminishing inflammation, astringing, stopping bleeding and the like. The components cooperate with each other to enhance the curative effect of the medicine, thereby achieving the purpose of preventing and treating chapped skin.
Whole blood donors who donate more frequency are more likely to develop iron deficiency, which could potentially affect the quality of the red blood cell (RBC) components during storage. Additional donor factors such as sex, age at donation, donor body mass index (BMI), as well as the manufacturing method could also affect RBC component quality, particularly haemolysis. The aim of this study was to examine the relationship between donation frequency, donor ferritin levels and BMI status on an extensive set of RBC characteristics in vitro, during storage at 2-6 °C for 42 days. A whole blood donation was collected from 787 Australian blood donors, held overnight, before top-and-bottom separation to produce RBC components. RBC components were tested using a panel of in vitro assays. Serum ferritin was tested from a sample taken at the time of donation, and donor demographic data was collected. Haemolysis in RBC components was not found to be associated with donation frequency. Increased red cell haemolysis, lactate concentration, extracellular potassium and RBC-derived microparticle numbers were significantly associated with a high BMI in male donors. There was also a trend towards increased red cell haemolysis in donors with ferritin concentrations in the upper range. Our findings indicate that although older male donors with potentially higher BMI are able to donate whole blood quite frequently, the resultant RBC components may have poorer in vitro quality.
The invention provides a monoclonal antibody which can simultaneously identify CVA6 hollow particles and solid particles and has neutralizing activity and application thereof. The amino acid sequences of the heavy chain complementarity determining regions CDR1, CDR2 and CDR3 of the monoclonal antibody are respectively shown as SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3; the amino acid sequences of the light chain complementarity determining regions CDR1, CDR2 and CDR3 are shown in SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6, respectively. The monoclonal antibody targets conformational epitopes, has neutralizing activity, can simultaneously identify CVA6 hollow particles and solid particles, can be used as CVA6 antigen detection antibodies, and is beneficial to accelerating the development process of hand-foot-and-mouth multivalent vaccines containing CVA6 pathogens.